

Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report

<https://marketpublishers.com/r/CCDA6E1E1CBEN.html>

Date: December 2010

Pages: 139

Price: US\$ 2,649.00 (Single User License)

ID: CCDA6E1E1CBEN

Abstracts

This market report from Select Biosciences presents a comprehensive industry analysis of the cancer vaccines space as well as that of the emerging circulating tumor cells (CTCs) space. These two areas are evolving and expanding driven by the greater emphasis on personalized medicine especially in the cancer/oncology space.

Cancer vaccines can be generated using a number of different approaches and this report describes these approaches vis-à-vis their advantages and disadvantages and associated technical characteristics. Indeed, the FDA-approval of a cancer vaccine for prostate cancer in 2010 was a key milestone in this space and a driver for R&D efforts forward. This report presents the pre-clinical pipeline, early-stage clinical trial pipeline, and the late-stage clinical pipeline for the cancer vaccines space. Also presented are the failed vaccine candidates with a discussion about these failures and how the industry can benefit via a deeper understanding of what components are required for effective immune system activation in vivo and effective vaccination—either preventative or therapeutic.

This report also examines the technology and market landscape for circulating tumor cells (CTCs). There is currently much interest in CTCs as they may offer a highly-sensitive biomarker for cancer detection via a minimally-invasive route. The cancer research field is currently seeking to understand the role of CTCs in metastases and in this vein this report is highly-useful in that it frames the biology of CTCs, characteristics of CTCs, methodologies for CTC enrichment, CTC detection, and analytical methods. This report also snapshots the clinical trials being conducted currently involving CTCs.

Extensive Worldwide Technical and Market Analyses Presented in this Report:

Classification and Characterization of Cancer Vaccines

Various Approaches for the Generation of Cancer Vaccines

Anti-Cancer Vaccination Strategies

Tumor Associated Antigens (TAAs)

Tumor Specific Antigens (TSAs)

Failed Anti-Cancer Vaccine Candidates and Reasons for such Failure

Strategies to Improve Success of Cancer Vaccines

US FDA-Approved Cancer Vaccines

Therapeutic Cancer Vaccines Approved in Various Countries Around the World

Cancer Vaccine Pipeline in Late-Stage Clinical Trials

Cancer Vaccine Pipeline in Early-Stage Clinical Trials

Pre-Clinical Cancer Vaccine Pipeline

Personalized Cancer Vaccination Strategies

Biology and Characteristics of CTCs

Methodologies/Various Technologies for Enrichment, Detection, and Characterization of CTCs

More details of the scope of coverage of this industry report are found in the Table of Contents (TOC) for the report—see below for link to downloadable PDF of the TOC

Contents

CHAPTER I. EXECUTIVE OVERVIEW

CHAPTER II. CANCER VACCINES: TECHNOLOGY & MARKET ANALYSIS

Cancer Immunotherapy Overview
Historical Milestones in Cancer Immunotherapy
Classification of Cancer Vaccines
Tumor Associated Antigens (TAAs)
Tumor Specific Antigens (TSAs)
Anti-Cancer Vaccination Strategies
Failed Therapeutic Cancer Vaccine Candidates
Strategies to Improve Success of Cancer Vaccines
Cancer Vaccines Market Overview
US FDA-Approved Cancer Vaccines: Preventative & Therapeutic
Therapeutic Cancer Vaccines Approved in Various Countries
Cancer Vaccine Pipeline in Phase III Clinical Trials
Early Stage (Phases I & II) Pipeline
Pre-Clinical Pipeline
Personalized Vaccines

CHAPTER III. CIRCULATING TUMOR CELLS (CTCS): TECHNOLOGY & MARKET ANALYSIS

Metastasis and Epithelial-to-Mesenchymal Transition (EMT)
What are CTCs?
CTCs vs. DTCs
Clinical Relevance of CTCs
Characteristics of CTCs
Detection and Diagnostics of CTCs
Biology of CTCs
CTC Analysis Methodologies
CTC Enrichment, Detection, and Characterization Methods
Microfluidic Devices for CTC Detection
Clinical Trials Involving CTC Analysis

APPENDIX I. RESEARCH METHODOLOGY

I would like to order

Product name: Cancer Vaccines & Circulating Tumor Cells (CTCs) 2011 Report

Product link: <https://marketpublishers.com/r/CCDA6E1E1CBEN.html>

Price: US\$ 2,649.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCDA6E1E1CBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970